UK authority gives Aspen maximum fine over life-saving drug
Aspen Pharmacare entered into an illegal agreement with two other drug companies over a corticosteroid supplied to the NHS
09 July 2020 - 09:34
The UK Competition and Markets Authority (CMA) said on Thursday that it has imposed a £2.1m (R45m) fine on Aspen Pharmacare for entering into an illegal agreement that allowed it to hike the price of a life-saving drug.
Aspen said in August that it had reached a settlement and admitted liability for entering into an agreement relating to the supply of fludrocortisone in the UK, which is used to treat adrenal insufficiency...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.